In another signal of the deepening relationship between the pharma and AI sectors, Novartis chief executive Vas Narasimhan ...

Parkinson’s disease (PD) is entering a pivotal phase. For decades, treatment has centred on dopamine replacement to manage ...

Infectious disease experts from around the world are calling for concerted action to combat a "silent surge" in resistance to ...

Japanese pharma group Daiichi Sankyo has reached a deal to sell its consumer healthcare division to food and beverage giant ...

The Michael J Fox Foundation for Parkinson's Research (MJFF) has started working with Swiss biotech Biognosys on a project ...

Amazon has pitched an AI-powered drug discovery platform to the biopharma industry that it says brings together computational ...

For too long, MASLD care has relied on a narrow playbook: lifestyle advice, routine monitoring, and waiting for signs of ...

The FDA may have approved Eli Lilly's oral weight-loss drug Foundayo in record time, but it still needs to see more safety ...

Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...

Rare neurological disease has undergone a meaningful shift over the past decade. Advances in human genetics, expanded access ...

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare ...

For now, the FDA is simply asking trial sponsors to make sure they meet the required reporting standards, but it has also ...